

4. If the investigator was blinded to the group allocation during the experiment and/or when assessing the outcome, state the extent of blinding. (Give section/paragraph or page #)

| |
|--|
| |
|--|

For animal studies, include a statement about blinding even if no blinding was done.

| |
|--|
| |
|--|

5. For every figure, are statistical tests justified as appropriate?

| |
|--|
| |
|--|

Do the data meet the assumptions of the tests (e.g. normal distribution)?

| |
|--|
| |
|--|

Is there an estimate of variation within each group of data?

| |
|--|
| |
|--|

Is the variance similar between the groups that are being statistically compared? (Give section/paragraph or page #)

| |
|--|
| |
|--|

Z P v š •

Reported in section/paragraph or page #

6. Report the source of antibodies (vendor and catalog number)

| |
|--|
| |
|--|

7. Identify the source of cell lines and report if they were recently authenticated (e.g., by STR profiling) and tested for mycoplasma contamination

| |
|--|
| |
|--|

v]u o D} o •

Reported in section/paragraph or page #

8. Report species, strain, sex and age of animals

| |
|--|
| |
|--|

9. For experiments involving live vertebrates, include a statement of compliance with ethical regulations and identify the committee(s) approving the experiments.

| |
|--|
| |
|--|

10. We recommend consulting the ARRIVE guidelines (<https://www.nature.com/articles/nrn38710>) to ensure that other relevant aspects of animal studies are adequately reported.

• μ u v • μ i š •

Reported in section/paragraph or page #

11. Identify the committee(s) approving the study protocol.

| |
|--|
| |
|--|

12. Include a statement confirming that informed consent was obtained from all subjects.

| |
|--|
| |
|--|

13. For publication of patient photos, include a statement confirming that consent to publish was obtained.

| |
|--|
| |
|--|

14. Report the clinical trial registration number (a ClinicalTrials.gov or equivalent).

| |
|--|
| |
|--|

15. For phase II and III randomized controlled trials, please refer to the [CONSORT statement](#) and submit the CONSORT checklist with your submission.

16. For tumor marker prognostic studies, we recommend that you follow the [REMARK reporting guidelines](#)

š % } •] š] } v

Reported in section/paragraph or page #

17. Provide accession codes for deposited data. Data deposition in a public repository is mandatory for:
a. Protein, DNA and RNA sequences
b. Macromolecular structures
c. Crystallographic data for small molecules
d. Microarray data

| |
|--|
| |
|--|

Deposition is strongly recommended for many other datasets for which structured public repositories exist; r details on our data policy are available in the Guide to Authors. We encourage the provision of other source in supplementary information in unstructured repositories such as [Figshare](#) and [Dryad](#). We encourage publication of Data Descriptors (see [Scientific Data](#)) to maximize data reuse

18. If computer code was used to generate results, include a statement in the Methods section indicating whether and how the code can be accessed. Include version information as necessary and any restrictions on availability.

| |
|--|
| |
|--|